Can I Take Turmeric / Curcumin With Vyvanse?

The direct answer

Turmeric and curcumin have no documented pharmacokinetic interaction with Vyvanse, and none is mechanistically expected, because lisdexamfetamine is converted to active d-amphetamine by enzymes in red blood cells rather than by the liver enzymes curcumin affects in laboratory studies. The unresolved question is pharmacodynamic: curcumin has shown antiplatelet activity in small human studies at doses well above typical supplement servings, and Vyvanse independently raises blood pressure and heart rate at therapeutic doses. No trial has combined the two agents, so the size of any additive cardiovascular or bleeding-risk effect in real patients is not established, and people already on blood thinners or with cardiovascular disease should raise this combination with their prescriber before using high-dose curcumin.

How Vyvanse is activated and cleared

Vyvanse is inactive as swallowed. Intestinal and red-blood-cell peptidase enzymes cleave lisdexamfetamine to release d-amphetamine, the molecule responsible for its stimulant effect. This conversion step, not hepatic cytochrome P450 (CYP450) metabolism, controls how much active drug reaches circulation. The FDA-approved prescribing information for Vyvanse describes lisdexamfetamine as not appreciably metabolized by CYP450 enzymes, and describes d-amphetamine itself as not a significant inhibitor or inducer of those enzymes. Readers who want the exact current label language should consult the FDA's own posted label, since label text is periodically revised.

Once active, d-amphetamine is cleared largely by the kidneys, and urine pH affects how quickly that happens: alkalinizing agents slow elimination and acidifying agents speed it up. Curcumin at typical supplement or dietary intake is not known to meaningfully shift urine pH, so this clearance pathway is unlikely to be affected either.

This is the practical reason most CYP450-based drug-supplement interactions do not apply to Vyvanse: the drug's activation step bypasses the liver enzymes that supplements like curcumin, St. John's wort, or grapefruit compounds typically influence.

What curcumin does that could matter here

Curcumin is the main studied polyphenol in turmeric. In laboratory (in vitro) systems it inhibits several CYP450 enzymes, including CYP3A4 and CYP1A2. That inhibition is pharmacologically real, but because Vyvanse does not depend on those enzymes for activation or clearance, it does not translate into an expected change in Vyvanse blood levels. It remains relevant for other medications a patient may take alongside Vyvanse, which is a separate conversation for a pharmacist.

The more consequential signal is curcumin's effect on platelets. A small human pilot study (reported decades ago, involving a handful of healthy volunteers) found that oral curcumin at a high dose reduced markers of platelet aggregation. Subsequent laboratory and animal work has described mechanisms by which curcumin could reduce thromboxane production and platelet-activating factor signaling. These findings support biological plausibility for an antiplatelet effect at high curcumin exposure, but the human dose-response relationship, and whether ordinary dietary turmeric or standard-dose supplements reach that threshold, has not been well characterized in large trials. Readers should treat any specific numeric dose threshold from older literature as needing confirmation rather than as an established clinical cutoff, and a pharmacist can help verify current sourcing before relying on it.

Why formulation changes the risk picture

Plain curcumin powder is poorly absorbed on its own. Formulations built with piperine (black pepper extract), phospholipid complexes, or nanoparticle delivery are marketed specifically because they raise plasma curcumin levels well above what plain powder achieves. A person taking an enhanced-bioavailability product at a modest listed dose may be getting an internal exposure closer to a much higher raw dose. That matters because most of the antiplatelet signal in the literature comes from higher-exposure conditions, not from turmeric used as a cooking spice.

Does the combination change how well Vyvanse works?

No published data addresses Vyvanse efficacy specifically with curcumin co-administration. Mechanistically, curcumin does not appear to compete with amphetamine at the dopamine transporter or vesicular monoamine transporter, and it does not alter the red-blood-cell conversion step that activates lisdexamfetamine. Based on that, curcumin is not expected to blunt or boost Vyvanse's therapeutic effect at standard supplement doses. Curcumin has been studied separately for possible mood and cognitive effects, including in trials looking at depression symptoms and memory measures in unrelated populations, but whether any of that overlaps meaningfully with a stimulant's effect on attention or mood in ADHD or binge eating disorder has not been studied and should not be assumed either way.

Who should have this conversation with a prescriber before combining them

Anyone on an anticoagulant or antiplatelet medication. Warfarin, clopidogrel, and aspirin all affect clotting through their own mechanisms. Case reports and pharmacology reviews have raised concern about turmeric intensifying anticoagulant effects, particularly with warfarin, though individual case reports are not proof of a reliable population-level effect. Layering high-dose curcumin on top of Vyvanse plus an anticoagulant creates a combination a physician should evaluate directly rather than one to self-manage.

Anyone with hypertension or existing cardiovascular disease. Vyvanse's label carries warnings around cardiovascular risk, including contraindications in certain structural heart conditions, and amphetamines are known to raise blood pressure and heart rate at therapeutic doses. Curcumin's antiplatelet activity does not treat cardiovascular disease and should never substitute for prescribed cardiovascular medication.

Anyone scheduled for surgery. General anesthesia guidance has long recommended stopping many herbal supplements roughly two weeks before elective surgery because of bleeding-risk concerns with several botanicals. Curcumin's antiplatelet potential places it in that general caution category. Vyvanse has its own separate perioperative considerations that should be coordinated with the prescribing clinician and anesthesia team, not inferred from this article.

Evidence-status interaction assessment

What we still do not know

No prospective study has enrolled patients taking both lisdexamfetamine and curcumin to measure outcomes directly. The reasoning in this article rests on separate, independently established facts about each agent rather than on a study of the combination itself. That gap does not mean the combination is dangerous. It means the reassurance available here is inferential, not empirical, and it should be treated that way, especially for patients who already carry bleeding or cardiovascular risk factors. Supplement use is also known to be under-reported to prescribers in general clinical practice, which makes real-world interaction signals harder to detect even when they occur.

Practical guidance by dose range

These are evidence-informed general principles, not individualized dosing instructions, and they do not replace a conversation with the clinician managing your Vyvanse prescription.

Standard supplement range (roughly 500-1,000 mg curcumin/day, no piperine). Considered lower risk for otherwise healthy adults on Vyvanse alone. No timing separation is needed, because the concern is pharmacodynamic, not absorption-based.

Moderate range (roughly 1,000-2,000 mg/day, or lower doses with piperine or other absorption enhancers). Mention it to your prescriber. Watch for unusual bruising or slow-stopping bleeding from minor cuts. Avoid stacking additional over-the-counter antiplatelet agents like ibuprobrand NSAIDs without guidance.

High range (above roughly 2,000 mg/day, or any enhanced-bioavailability product at higher listed doses). This is the range closest to where antiplatelet effects have been observed in small studies. It warrants direct prescriber review, particularly for anyone on anticoagulants, with a bleeding history, or with cardiovascular disease.

Monitoring checklist

• Tell your prescriber and pharmacist the exact product name, dose per serving, and whether it contains piperine or another bioavailability enhancer.
• If you take warfarin or another anticoagulant, ask whether an INR or coagulation check is warranted after starting or changing curcumin dose.
• Report new bruising, prolonged bleeding from minor cuts, palpitations, or chest discomfort rather than assuming they are unrelated.
• Do not stop or start high-dose curcumin in the days immediately before a planned surgery without clearing it with both your surgical team and your Vyvanse prescriber.

Key takeaways

A pharmacokinetic interaction between turmeric or curcumin and Vyvanse is unlikely because lisdexamfetamine's activation bypasses the liver enzymes curcumin affects. The realistic area of caution is pharmacodynamic: curcumin's antiplatelet activity at higher doses combined with Vyvanse's cardiovascular stimulant effects. Standard supplement doses appear lower risk for healthy adults; higher doses, enhanced-bioavailability products, anticoagulant use, and pre-existing cardiovascular disease all raise the bar for needing a direct prescriber conversation before combining the two. No study has tested the combination directly, and that gap should be stated plainly rather than smoothed over.